GR3030219T3 - LIVER-STAGE-SPECIFIC PEPTIDE SEQUENCES OF -i(P. FALCIPARUM) BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES - Google Patents

LIVER-STAGE-SPECIFIC PEPTIDE SEQUENCES OF -i(P. FALCIPARUM) BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES

Info

Publication number
GR3030219T3
GR3030219T3 GR990401305T GR990401305T GR3030219T3 GR 3030219 T3 GR3030219 T3 GR 3030219T3 GR 990401305 T GR990401305 T GR 990401305T GR 990401305 T GR990401305 T GR 990401305T GR 3030219 T3 GR3030219 T3 GR 3030219T3
Authority
GR
Greece
Prior art keywords
falciparum
peptide sequences
liver
molecule
stage
Prior art date
Application number
GR990401305T
Other languages
English (en)
Inventor
Claudine Guerin-Marchand
Pierre Druilhe
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of GR3030219T3 publication Critical patent/GR3030219T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GR990401305T 1991-02-05 1999-05-13 LIVER-STAGE-SPECIFIC PEPTIDE SEQUENCES OF -i(P. FALCIPARUM) BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES GR3030219T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9101286A FR2672290B1 (fr) 1991-02-05 1991-02-05 Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
PCT/FR1992/000104 WO1992013884A1 (fr) 1991-02-05 1992-02-05 Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.

Publications (1)

Publication Number Publication Date
GR3030219T3 true GR3030219T3 (en) 1999-08-31

Family

ID=9409373

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401305T GR3030219T3 (en) 1991-02-05 1999-05-13 LIVER-STAGE-SPECIFIC PEPTIDE SEQUENCES OF -i(P. FALCIPARUM) BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES

Country Status (11)

Country Link
US (5) US6319502B1 (el)
EP (1) EP0570489B1 (el)
AT (1) ATE179718T1 (el)
CA (3) CA2101924C (el)
DE (1) DE69229107T2 (el)
DK (1) DK0570489T3 (el)
ES (1) ES2133316T3 (el)
FR (1) FR2672290B1 (el)
GR (1) GR3030219T3 (el)
HK (1) HK1014012A1 (el)
WO (1) WO1992013884A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
US8450067B2 (en) * 2002-05-28 2013-05-28 Omrix Biopharmaceuticals Inc. Method for obtaining anti-idiotype antibodies
WO2004044167A2 (en) * 2002-11-12 2004-05-27 Walter Reed Army Institute Of Research Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
KR101035111B1 (ko) * 2004-06-30 2011-05-19 주식회사 엘지생명과학 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단
CN101516396B (zh) 2006-09-26 2013-10-09 传染性疾病研究院 包含合成佐剂的疫苗组合物
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EA020950B1 (ru) 2007-09-17 2015-03-31 Баррик Гольд Корпорейшн Способ усовершенствования восстановления золота из двойных тугоплавких золотосодержащих руд
US8262770B2 (en) 2007-09-18 2012-09-11 Barrick Gold Corporation Process for controlling acid in sulfide pressure oxidation processes
WO2009037594A2 (en) * 2007-09-18 2009-03-26 Barrick Gold Corporation Process for recovering gold and silver from refractory ores
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN103491979B (zh) 2010-12-06 2016-12-21 马尔瓦有限责任公司 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3915579A1 (en) 2013-12-31 2021-12-01 Infectious Disease Research Institute Single vial vaccine formulations
IL298227B1 (en) 2016-06-01 2024-05-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569722B2 (en) * 1983-01-28 1988-02-18 Saramane Pty Ltd Expression of plasmodium falciparum polypeptides from cloned cdna
IL76338A (en) * 1984-09-11 1994-08-26 Saramane Pty Ltd Plasmodium plasmodium immunogenic polypeptides, AND molecules encoding them, a method for preparing the polypeptides and preparations containing the polypeptide
ZW8386A1 (en) * 1985-04-11 1986-07-23 Inst Medical W & E Hall Highly repetitive antigens of plasmodium falciparum
EP0297110A4 (en) * 1986-03-14 1989-12-19 Saramane Pty Ltd POLYPEPTIDES WITH IMMUNE AGAINST MALARIA.
US6270771B1 (en) * 1988-10-06 2001-08-07 Institut Pasteur Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
FR2610631B1 (fr) * 1987-02-09 1989-11-24 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
AU4661889A (en) * 1988-11-30 1990-06-26 Biomedical Research Institute A novel malarial sporozoite and exoerythrocytic peptide antigen
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
GB9020438D0 (en) * 1990-09-19 1990-10-31 Imperial College Plasmodium liver stage antigens
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US5602831A (en) * 1995-03-31 1997-02-11 Seiko Communications Systems, Inc. Optimizing packet size to eliminate effects of reception nulls
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
CN1244126A (zh) * 1997-01-21 2000-02-09 纽约大学 用于抗疟疾疫苗的通用t细胞表位
US6828416B1 (en) * 1998-08-21 2004-12-07 The United States Of America As Represented By The Department Of Health And Human Services Recombinant multivalent malarial vaccine against Plasmodium falciparum
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
EP1390401A2 (fr) * 2001-05-16 2004-02-25 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US8232255B2 (en) * 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria

Also Published As

Publication number Publication date
DE69229107D1 (de) 1999-06-10
FR2672290B1 (fr) 1995-04-21
EP0570489B1 (fr) 1999-05-06
US7087231B2 (en) 2006-08-08
DE69229107T2 (de) 1999-12-16
US6319502B1 (en) 2001-11-20
HK1014012A1 (en) 1999-09-17
CA2495581C (fr) 2008-10-21
US20020041882A1 (en) 2002-04-11
US20030064075A1 (en) 2003-04-03
US7332595B2 (en) 2008-02-19
US7438917B2 (en) 2008-10-21
FR2672290A1 (fr) 1992-08-07
WO1992013884A1 (fr) 1992-08-20
EP0570489A1 (fr) 1993-11-24
US20060182769A1 (en) 2006-08-17
CA2495581A1 (fr) 1992-08-20
ES2133316T3 (es) 1999-09-16
US20080213795A1 (en) 2008-09-04
CA2101924A1 (fr) 1992-08-06
CA2101924C (fr) 2005-06-28
ATE179718T1 (de) 1999-05-15
CA2638662A1 (fr) 1992-08-20
DK0570489T3 (da) 2000-01-03

Similar Documents

Publication Publication Date Title
GR3030219T3 (en) LIVER-STAGE-SPECIFIC PEPTIDE SEQUENCES OF -i(P. FALCIPARUM) BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES
CA2290485A1 (en) Method for the production of non-immunogenic proteins
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
CY2043A (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
MY102594A (en) Expression of plasmodium falciparum polypeptides from cloney cdna
GEP20012421B (en) Method for Typing Hepatitis C Virus and Reagents for Use Therein
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
EP0869177A3 (en) Human a- and b- platelet-derived growth factor receptor proteins and uses therefor.
DE3667061D1 (en) New protein isolated from blood, process for preparing said protein, antibodies against said new protein, and pharmaceutical compositions containing said protein or said antibodies
EP0253325A3 (en) Oncogene-related peptides
CA2010256A1 (en) Protein anti-cancer agent
EP0348725A3 (en) Species-specific epitode of chlamydia trachomatis and antibodies that recognize the same
EP0293827A3 (en) Assay for leishmaniasis
ES2006730A6 (es) Un metodo de preparar un peptido o polipeptido sintetico que presenta la antigenicidad de la totalidad o una parte de un antigeno de p. falciparum
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
ES2005753A6 (es) Procedimiento para la preparacion de polipeptidos inmunologicamente activos utiles para la obtencion de vacunas antimalaria y para la deteccion de enfermedades paludicas.
MY102593A (en) Antigents of plasmodium falciparum
AU6393990A (en) Hiv related peptides
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.
JPS6490197A (en) Peptide
Lorenzini et al. Biotech RIA 85" International Symposium on The Impact of Biotechnology on Diagnostics
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus